Bank of America Corp DE Has $6.60 Million Stock Holdings in Cerus Co. (NASDAQ:CERS)

Bank of America Corp DE boosted its holdings in shares of Cerus Co. (NASDAQ:CERS) by 107.3% in the second quarter, according to its most recent filing with the SEC. The firm owned 1,173,714 shares of the biotechnology company’s stock after acquiring an additional 607,480 shares during the period. Bank of America Corp DE owned 0.84% of Cerus worth $6,596,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in CERS. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in Cerus by 444.4% during the 2nd quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 5,049,385 shares of the biotechnology company’s stock worth $28,378,000 after acquiring an additional 4,121,845 shares during the period. Nikko Asset Management Americas Inc. grew its holdings in Cerus by 434.1% during the 2nd quarter. Nikko Asset Management Americas Inc. now owns 5,049,385 shares of the biotechnology company’s stock worth $28,378,000 after acquiring an additional 4,103,996 shares during the period. ARK Investment Management LLC grew its holdings in Cerus by 11.2% during the 2nd quarter. ARK Investment Management LLC now owns 8,493,022 shares of the biotechnology company’s stock worth $47,731,000 after acquiring an additional 853,589 shares during the period. First Midwest Bank Trust Division grew its holdings in Cerus by 435.5% during the 2nd quarter. First Midwest Bank Trust Division now owns 915,165 shares of the biotechnology company’s stock worth $5,143,000 after acquiring an additional 744,254 shares during the period. Finally, Peregrine Capital Management LLC grew its holdings in Cerus by 13.4% during the 2nd quarter. Peregrine Capital Management LLC now owns 2,194,628 shares of the biotechnology company’s stock worth $12,334,000 after acquiring an additional 259,932 shares during the period. 72.94% of the stock is owned by hedge funds and other institutional investors.

A number of analysts have commented on CERS shares. Stephens started coverage on shares of Cerus in a report on Thursday, August 22nd. They set an “overweight” rating and a $8.00 target price for the company. BidaskClub lowered shares of Cerus from a “hold” rating to a “sell” rating in a report on Friday, October 4th. Zacks Investment Research raised shares of Cerus from a “sell” rating to a “hold” rating in a report on Monday, October 7th. Stifel Nicolaus began coverage on shares of Cerus in a report on Tuesday, August 27th. They set a “buy” rating and a $7.00 target price for the company. Finally, ValuEngine raised shares of Cerus from a “hold” rating to a “buy” rating in a report on Wednesday, October 2nd. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. Cerus currently has a consensus rating of “Buy” and a consensus target price of $7.63.



Shares of CERS stock opened at $4.49 on Friday. Cerus Co. has a 12-month low of $4.32 and a 12-month high of $7.06. The firm has a market capitalization of $623.73 million, a price-to-earnings ratio of -10.20 and a beta of 1.64. The company has a quick ratio of 2.33, a current ratio of 2.67 and a debt-to-equity ratio of 0.88. The firm has a fifty day moving average of $5.08 and a 200-day moving average of $5.42.

Cerus (NASDAQ:CERS) last announced its quarterly earnings results on Thursday, August 1st. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.12) by ($0.01). Cerus had a negative net margin of 98.69% and a negative return on equity of 85.73%. The firm had revenue of $18.20 million during the quarter, compared to analyst estimates of $17.55 million. During the same period last year, the firm earned ($0.10) EPS. Cerus’s quarterly revenue was up 18.2% on a year-over-year basis. Research analysts expect that Cerus Co. will post -0.48 earnings per share for the current year.

In other news, insider Richard J. Benjamin sold 16,444 shares of the business’s stock in a transaction on Wednesday, August 7th. The shares were sold at an average price of $5.01, for a total value of $82,384.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Carol Moore sold 30,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $5.33, for a total transaction of $159,900.00. The disclosure for this sale can be found here. Insiders sold a total of 74,903 shares of company stock valued at $394,513 in the last three months. 7.26% of the stock is owned by company insiders.

Cerus Profile

Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.

Recommended Story: What are momentum indicators and what do they show?

Institutional Ownership by Quarter for Cerus (NASDAQ:CERS)

Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.